{"title":"更正“丝裂原活化蛋白激酶抑制通过上调人白细胞抗原增强T细胞对表达hoxb7的肿瘤的反应”。","authors":"","doi":"10.1111/cas.70094","DOIUrl":null,"url":null,"abstract":"<p>Komatsuda H, Wakisaka R, Kono M, et al. Mitogen-activated protein kinase inhibition augments the T cell response against <i>HOXB7</i>-expressing tumor through human leukocyte antigen upregulation. <i>Cancer Sci</i>. 2023;114:399–409. doi: 10.1111/cas.15619</p><p>In the above article, there were errors in the following texts:</p><p>From Section 3.2:</p><p>Based on computer-based algorithms, <i>HOXB7</i><sub>8-25</sub> (PLLLKLLKSVGAQKD) was selected as a potential candidate for eliciting antigen-specific HTL responses.</p><p>The correct text should be as follows:</p><p>Based on computer-based algorithms, <i>HOXB7</i><sub>8-25</sub> (NTLFSKYPASSSVFATGA) was selected as a potential candidate for eliciting antigen-specific HTL responses.</p><p>From Section 4:</p><p>As <i>HOXB7</i><sub>18-26</sub> (SSVFAPGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of <i>HOXB7</i><sub>8-25</sub> to <i>HOXB7</i><sub>8-26</sub> would improve the antigenicity of the peptide by inducing both HTLs and CTLs.</p><p>The correct text should be as follows:</p><p>As <i>HOXB7</i><sub>18-26</sub> (SSVFATGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of <i>HOXB7</i><sub>8-25</sub> to <i>HOXB7</i><sub>8-26</sub> would improve the antigenicity of the peptide by inducing both HTLs and CTLs.</p><p>We apologize for these errors.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 7","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70094","citationCount":"0","resultStr":"{\"title\":\"Correction to “Mitogen-Activated Protein Kinase Inhibition Augments the T Cell Response Against HOXB7-Expressing Tumor Through Human Leukocyte Antigen Upregulation”\",\"authors\":\"\",\"doi\":\"10.1111/cas.70094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Komatsuda H, Wakisaka R, Kono M, et al. Mitogen-activated protein kinase inhibition augments the T cell response against <i>HOXB7</i>-expressing tumor through human leukocyte antigen upregulation. <i>Cancer Sci</i>. 2023;114:399–409. doi: 10.1111/cas.15619</p><p>In the above article, there were errors in the following texts:</p><p>From Section 3.2:</p><p>Based on computer-based algorithms, <i>HOXB7</i><sub>8-25</sub> (PLLLKLLKSVGAQKD) was selected as a potential candidate for eliciting antigen-specific HTL responses.</p><p>The correct text should be as follows:</p><p>Based on computer-based algorithms, <i>HOXB7</i><sub>8-25</sub> (NTLFSKYPASSSVFATGA) was selected as a potential candidate for eliciting antigen-specific HTL responses.</p><p>From Section 4:</p><p>As <i>HOXB7</i><sub>18-26</sub> (SSVFAPGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of <i>HOXB7</i><sub>8-25</sub> to <i>HOXB7</i><sub>8-26</sub> would improve the antigenicity of the peptide by inducing both HTLs and CTLs.</p><p>The correct text should be as follows:</p><p>As <i>HOXB7</i><sub>18-26</sub> (SSVFATGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of <i>HOXB7</i><sub>8-25</sub> to <i>HOXB7</i><sub>8-26</sub> would improve the antigenicity of the peptide by inducing both HTLs and CTLs.</p><p>We apologize for these errors.</p>\",\"PeriodicalId\":9580,\"journal\":{\"name\":\"Cancer Science\",\"volume\":\"116 7\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70094\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cas.70094\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.70094","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Correction to “Mitogen-Activated Protein Kinase Inhibition Augments the T Cell Response Against HOXB7-Expressing Tumor Through Human Leukocyte Antigen Upregulation”
Komatsuda H, Wakisaka R, Kono M, et al. Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. Cancer Sci. 2023;114:399–409. doi: 10.1111/cas.15619
In the above article, there were errors in the following texts:
From Section 3.2:
Based on computer-based algorithms, HOXB78-25 (PLLLKLLKSVGAQKD) was selected as a potential candidate for eliciting antigen-specific HTL responses.
The correct text should be as follows:
Based on computer-based algorithms, HOXB78-25 (NTLFSKYPASSSVFATGA) was selected as a potential candidate for eliciting antigen-specific HTL responses.
From Section 4:
As HOXB718-26 (SSVFAPGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of HOXB78-25 to HOXB78-26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.
The correct text should be as follows:
As HOXB718-26 (SSVFATGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of HOXB78-25 to HOXB78-26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.
期刊介绍：
Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.
Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
